Ocular Oncology and Pathology

We conduct clinical and preclinical research to expand knowledge, improve survival and reduce suffering in eye cancer and diseases of the eyelids and lacrimal system.

A variety of different tumors can arise in the eye, in the eyelids and in the orbit. Some of these are benign, while others are malignant and very aggressive.

Uveal melanoma is the most common primary intraocular tumor in adults. Almost half of all patients develop metastases even if the eye has been removed. This is believed to be due to so-called micrometastases that leave the primary tumor very early. These micrometastases can remain dormant in their metastatic niche, including the bone marrow and liver, for several years. Once they leave dormancy and start growing, the patient’s prognosis is poor. Uveal melanoma is thereby a cancer disease with unpredictable, high mortality and limited treatment options. We would like to help remedy this. To this aim, we extend current knowledge in the field with clinical and preclinical research. We also develop prognostic test with high accuracy and conduct clinical trials with the aim to prevent the development of metastases.

The most common tumor in children is Retinoblastoma. In national and international collaboration, we research genetic aspects of the disease and evaluate the results of novel treatment regimens.

Research Projects

We perform translational research in clinical environments and laboratories. As both the affiliated researchers and the infrastructure are exclusively dedicated to ocular oncology and pathology, we aim to achieve and maintain excellence in this area.

Photo: Gustav Stålhammar

Selected publications

Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma

Gustav Stålhammar 1

Int J Radiat Oncol Biol Phys. 2023 Jul 9;S0360-3016(23)02197-1.doi: 10.1016/j.ijrobp.2023.06.077.

Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases

Viktor T Gill  1   2 , Emelie Norrman  2 , Shiva Sabazade  1   3 , Ali Karim  2 , Emma Lardner  3 , Gustav Stålhammar  1   3

Am J Clin Pathol. 2023 Apr 13;aqad029.doi: 10.1093/ajcp/aqad029.

Obesity paradox in uveal melanoma: high body mass index is associated with low metastatic risk

Shiva Sabazade  1   2 , Adrianna Opalko  3   2 , Christina Herrspiegel  3   2 , Viktor Torgny Gill  2   4 , Flavia Plastino  2 , Helder André  3   2 , Gustav Stålhammar  3   2

Br J Ophthalmol. 2023 Apr 7;bjo-2022-322877.doi: 10.1136/bjo-2022-322877.

A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival

Christina Herrspiegel #  1   2 , Flavia Plastino #  2 , Emma Lardner  1 , Stefan Seregard  1   2 , Pete A Williams  1   2 , Helder André  2 , Gustav Stålhammar  3   4

BMC Cancer. 2023 Mar 27;23(1):277.doi: 10.1186/s12885-023-10757-x.

Presenting Symptoms Are Associated with Uveal Melanoma-Related Death

Maria Fili  1 , Stefan Seregard  1 , Gustav Stålhammar  2

Ophthalmology. 2021 Jul;128(7):1107-1109.doi: 10.1016/j.ophtha.2020.11.023. Epub 2020 Nov 27.

Mapping of Perfusion During Full-Thickness Blepharotomy Using Laser Speckle Contrast Imaging

Anna H C Wiktorin  1 , Johanna V Berggren  2 , Malin Malmsjö  2 , Sandra Lindstedt  2 , Rafi Sheikh  2 , Elin Bohman  1

Ophthalmic Plast Reconstr Surg. 2022 Nov-Dec;38(6):588-592.doi: 10.1097/IOP.0000000000002218. Epub 2022 Jun 3.


Group leaders


Gustav Stålhammar

Research group leader

Stefan Seregard

Research group leader

Research team members

Content reviewer: